Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.

Jennifer Y BarracloughJie YuGemma A FigtreeVlado PerkovicHiddo J Lambers Heerspink Brendon L Neuen Christopher P CannonKenneth W MahaffeyAletta Elisabeth Schutte Bruce C Neal Clare Arnott

Published in: Diabetes, obesity & metabolism (2022)

Patients with T2D and PAD derived similar relative cardiorenal benefits from canagliflozin treatment but higher absolute benefits compared with those without PAD, with no increase in extended MALE.

Keyphrases

clinical trial
study protocol
electronic health record
quality improvement
phase iii
big data
phase ii
randomized controlled trial
type diabetes
skeletal muscle
insulin resistance
open label